Metastatic triple-negative breast cancer

Metastatic triple-negative breast cancer is an advanced, stage IV malignancy arising from breast tissue that has disseminated to distant anatomical sites, frequently involving the lungs, liver, brain, or bones

Metastatic triple-negative breast cancer is an advanced, stage IV malignancy arising from breast tissue that has disseminated to distant anatomical sites, frequently involving the lungs, liver, brain, or bones It is defined pathologically by the lack of significant expression of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2) amplification or overexpression This subtype exhibits aggressive clinical biology characterized by rapid disease progression...

Metastatic triple-negative breast cancer is an advanced, stage IV malignancy arising from breast tissue that has disseminated to distant anatomical sites, frequently involving the lungs, liver, brain, or bones

It is defined pathologically by the lack of significant expression of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2) amplification or overexpression

This subtype exhibits aggressive clinical biology characterized by rapid disease progression, high proliferative rates, and early relapse, disproportionately affecting younger premenopausal women, individuals of African or Hispanic descent, and carriers of germline BRCA mutations Because the tumor lacks classic hormonal and HER2 targets, management relies on systemic cytotoxic regimens often combined with biomarker-directed therapies such as immune checkpoint inhibitors, antibody-drug conjugates...

This subtype exhibits aggressive clinical biology characterized by rapid disease progression, high proliferative rates, and early relapse, disproportionately affecting younger premenopausal women, individuals of African or Hispanic descent, and carriers of germline BRCA mutations

Because the tumor lacks classic hormonal and HER2 targets, management relies on systemic cytotoxic regimens often combined with biomarker-directed therapies such as immune checkpoint inhibitors, antibody-drug conjugates, or PARP inhibitors